Advance late-stage pipeline
More energy –
Growing and delivering
Successfully launch our new products
Bring Idorsia to sustainable profitability
Fuel our pipeline with new discoveries
Utilize state-of-the-art technologies to drive innovation
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
We will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
We have identified five key strategic priorities to ensure the company’s success going forward.
Bring Idorsia to sustainable profitability
Financial information
Read our latest financial reports and updates on how we will achieve sustainable profitability
For investors, more information is available in the Innovation fact sheet.
Our Innovation
Our innovation is the basis for our long-term financial health. Read the latest news from across our portfolio.
Latest news
Successfully launch our new products
Our Strategic Priorities
We believe that our development compounds have the potential to significantly change treatment in their target diseases, resulting in medicines with substantial commercial potential.
Advance late-stage pipeline
Fuel our pipeline with new discoveries
Utilize state-of-the-art technologies to drive innovation
Artificial intelligence
Computer modeling
Drug Discovery
Patient reported outcome measures
Creative clinical endpoints
Clinical Development
Digital & Social Media
Advanced analytics
Commercialization
We have a diversified and balanced clinical development pipeline, covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.
The company also has a vaccine platform discovering and developing glycoconjugate vaccines containing synthetic antigenic glycan molecules with and without a carrier protein to prevent infection.
The pipeline comprises more than 10 compounds, with half in late-stage development. The development of an innovative compound into a future therapy is a complex undertaking, which inevitably involves an element of risk. With our scientific, data-driven approach helping to mitigate risk at each step, we have already brought two products to the market, QUVIVIQ™ in the US and Europe, and PIVLAZ(r) in Japan (license rights later assigned to Sosei Heptares for Japan, South Korea and APAC (ex-China)), with aprocitentan currently undergoing regulatory assessment in the US and EU.
“With patients at the heart of our process, our key assets have the potential to transform treatment
in the target indications.”
— Alberto Gimona
Head of Global Clinical Development
In order to successfully bring our pioneering therapies to patients and to maximize the value of our innovations, we will continue to build and strengthen our global commercial organization.
We have taken a simple, efficient approach to our first product launches, utilizing shared, best in class platforms and ways of working that enable fast decision-making and cost effective growth. We will continue to focus on transforming treatment in underserved markets, such as insomnia, and building new markets, such as cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage, using scientific and medical evidence to engage effectively with experts in the field and with payors. We plan to remain flexible and nimble in the way we commercialize our portfolio. We have built the core capabilities required to successfully launch our products, while also entering into partnerships where we need support to reach a primary care market.
“Idorsia has the ideal constellation for bringing successful medicines to the market.”
— Jean-Paul Clozel, CEO
We have established commercial operations in the US and the major European markets, with experienced leadership teams and strategic locations. We have also established a robust and lean global supply chain function to ensure consistent supplies of our innovative medicines to patients.
In addition to several drug candidates in the early stages of clinical and preclinical development, we must continue with our discovery efforts, to maintain a steady supply of innovative compounds to our pipeline. We aim to create a pipeline with a sales potential of at least CHF 5 billion.
We provide a supportive and stimulating environment for high-performing teams, recognizing and rewarding their contributions.
“Our approach: novel projects that answer medical problems in groundbreaking ways, balanced with less risky projects where we have a deep understanding of the disease mechanisms.”
— Martine Clozel, CSO
While launching our first marketed products and developing our late-stage clinical pipeline to bring our innovative therapies to patients, we also continue to discover new compounds.
We want our employees to feel proud of their work, and of the company they work for. We provide a supportive and stimulating environment for high-performing teams, recognizing and rewarding their contributions.
“Achieving our strategic priorities is dependent on a company-wide effort, so we must attract, retain, and develop a talented and engaged workforce. ”
— Jean-Paul Clozel, CEO
As we wish to remain at the cutting edge of science, it is vital that we consider innovative approaches and utilize state-of-the-art technologies at each stage of the process, from bench to bedside.
Our mid-term key priorities to achieve long-term success
We are building Idorsia with a long-term focus and ambitious aspirations. By advancing our development pipeline and successfully launching our first products, we aim to bring Idorsia to sustainable profitability as soon as possible.
We believe that we have the potential to generate significant revenues from our innovative portfolio, which now includes two products on the market, spanning multiple geographies.
— André C. Muller, CFO
We believe that we have the potential to generate significant revenues from our innovative portfolio, which now includes two products on the market, spanning multiple geographies.
To maximize the medical value of our discoveries and to provide a source of liquidity in the short to medium term, we have entered into several collaborative partnerships with pharmaceutical companies. These include development, commercialization, and revenuesharing agreements, under which we are eligible to receive milestone payments based on the progress of the development compound in question.
Revenues from milestones & royalty streams
Sales from our commercial products
We will generate our own sales income, starting with QUVIVIQ™ (daridorexant) in the US and Europe.
We are developing lucerastat for Fabry disease.
Cenerimod is in development for systemic lupus erythematosus.
Selatogrel is in development for suspected acute myocardial infarction.
PONVORY™ (ponesimod):
Several of our partnerships include development, commercialization and revenue-sharing agreements, under which we are eligible to receive milestone payments based on the progress of the development compound in question.
Aprocitentan:
T-type calcium channel blocker:
Vamorolone:
Furthermore, with several unencumbered assets in clinical development, additional contract revenue from partnerships and/or out-licensing remains an option for us.
Read more about our Partnerships
Our strategy to reach profitability relies on dual revenue streams...
Target therapeutic areas
Portfolio
Compound: Lucerastat
Mechanism of action: Glucosylceramide synthase inhibitor
Status: Phase 3 primary endpoint not met, Open Label Extension study (OLE) ongoing
1
Fabry disease
Compound: Selatogrel
Suspected acute myocardial infarction
Mechanism of action: P2Y inhibitor
Status: Phase 3 recruiting
Compound: Clazosentan
Systemic lupus erythematosus
Mechanism of action: S1P receptor modulator
Status: Phase 3 recruiting
Compound: Aprocitentan
Difficult-to-control (resistant) hypertension
Mechanism of action: Dual endothelin receptor antagonist
Status: NDA under review in the US, MAA under review in the EU, other filings in preparation
Compound: QUVIVIQ™ (daridorexant)
Insomnia
Mechanism of action: Dual orexin receptor antagonist
Status: Commercially available in the US, Germany, Italy, Switzerland, Spain, and the UK; approved in the EU and Canada; Filing in Japan expected H2 2023; Phase 2 in pediatric insomnia – recruiting
Read about the science and unmet medical need in Fabry disease.
Fabry Disease
Understand more about heart attack and how it’s impacting patients.
Acute Myocardial Infarction
Want to know more about lupus?
Visit our ebook.
Systemic lupus erythematosus
Visit our ebook for more information about difficult-to-control hypertension.
Difficult-to-control hypertension
Insomnia
Read more
Visit the ebook to learn about the burden of insomnia.
Read more
Read more
Read more
Read more
Start motion
Stop motion
Learn more
Learn more
Learn more
Learn more
Learn more
Read more
Read more
Read more
Read more
Click the arrows to navigate between countries.
Click the pin to find out more.
Asia
3/3
Tokyo, Japan
Satoshi Tanaka
President, Idorsia Japan
Founded 2018
Midtown East
9-7-2 Akasaka Minato-ku
Tokyo 107-0052, Japan
Idorsia Pharmaceuticals Japan Ltd
www.idorsia.jp
Madrid, Spain
Manuel Ortega
General Manager Spain
Founded 2021
Paseo Castellana 79
28046, Madrid
Spain
Idorsia Pharmaceuticals Spain S.L.
London,
United Kingdom
Robert Moore
General Manager UK
Founded 2021
20 Eastbourne Terrace
London, W2 6LG
United Kingdom
Idorsia Pharmaceuticals UK Ltd
Paris, France
Dominique Le Terrier
General Manager France
Founded 2021
16 Rue Washington
75008, Paris, Ile de France
France
Idorsia Pharmaceuticals France SAS
www.idorsia.fr
Switzerland,
Allschwil
Idorsia Global Commercial Operations
Alice Huismann
General Manager Switzerland & Austria
Founded 2017
Headquarters of Idorsia Ltd.
Hegenheimermattweg 91
4123 Allschwil
Switzerland
Idorsia Pharmaceuticals Ltd
www.idorsia.com
Milan, Italy
Francesco Scopesi
General Manager Italy
Founded 2021
Via Fabio Filzi 25A
20124 Milano
Italy
Idorsia Pharmaceuticals Italy S.R.L.
Munich, Germany
Thorsten Löchle
General Manager Germany
Founded 2021
Luise-Ullrich-Strasse 20
DE-80636 München
Germany
Idorsia Pharmaceuticals Germany GmbH
Europe
2/3
North America
1/3
Radnor, Pennsylvania, USA
Tausif (‘Tosh’) Butt
President, Idorsia US
Founded 2020
One Radnor Corporate Center, Suite 101
100 Matsonford Rd
Radnor, PA 19087
United States
Idorsia Pharmaceuticals US Inc.
www.idorsia.us
Sales from our marketed products will be followed by other products from our late-stage clinical pipeline:
Targets
Hits
Lead Structure
Improved Leads
Compound Library
Preclinical Development
Drug Development
Clinical Development
Registration
Launch
Molecular Biology
(Target Finding)
Biochemistry
(High Throughput Screening)
Structural Biology
and Molecular Modeling
Research
Information
Management
Medicinal
Chemistry
Pharmacokinetics & Metabolism
Chemistry
Process R&D
Pharmacology
Molecular Biology
(Target Finding)
Our work in the lab begins with the target. This may be a particular protein which, when its activity is modulated, can normalize a biological process in the body – with beneficial effects for patients. To see whether we can affect the protein’s activity, we first need to be able to measure it.
We produce, or “express”, the target in large quantities and measure its natural activity in assays. The assay needs to be sensitive, accurate and highly reliable. Plus, in order to perform hundreds of thousands of measurements, it needs to be automated, using robotic equipment.
Biochemistry
(High Throughput Screening)
But there are two sides to the discovery process – a target and a compound.
Compounds are substances which, we hope, will modify the activity of a target involved in a pathological process and which can be developed into a drug for patients.
At Idorsia, we maintain a library consisting of hundreds of thousands of different compounds. To begin our hunt for drugs, we test the entire library on the target, in the hope that one of these compounds will modify the activity of the protein. This process is called high-throughput screening; if it’s a simple assay, we can test the whole library within a matter of weeks. At this stage, the goal is to identify compounds which exhibit some activity.
Structural Biology and
Molecular Modeling
Our experts in structural biology and molecular modeling then analyze these compounds to decide which of them is the most promising starting point for optimization using the art of medicinal chemistry.
Target and compound fit together like a lock and a key. The compound can be modified so that it fits better and, ideally, becomes more potent.
Research Information Management
Throughout the drug discovery process, huge amounts of data are generated, and powerful IT tools are required to extract the knowledge we need. To really understand the data, we visualize it and study the relationship between chemical structures and biological properties.
Medicinal Chemistry
Medicinal chemistry involves the use of chemistry’s tools to design molecules that are potential drugs. We manipulate the molecular structure and then send the compounds back to our biologists or pharmacologists for testing in an iterative process. With each cycle, the compound is further optimized to finally become a drug.
Pharmacokinetics & Metabolism
At this point, we also study how the drug substance moves through the body. This is vital to understand key factors such as the duration of the treatment effect and intensity, which helps determine the appropriate dose.
Chemistry Process R&D
Small-scale testing for initial assays requires only milligram quantities; for subsequent testing, however, much more material is needed. This is where our process research teams come into the picture. They are responsible for scaling up from milligram to gram quantities, and finally to the kilogram batch which is used for preclinical testing.
It’s no good having a potent compound which is destroyed by the body before it has a chance to do its job. Our chemical and drug product specialists take a compound which has been optimized by the chemists and develop the most robust, safe and cost-efficient processes for the drug substance, the formulation, and packaging materials.
Once reproducible processes have been elaborated to produce large quantities of the active compound and the formulated drug product, our technical project teams manage the production of the drug with partner companies. They secure drug supplies for clinical development and, when appropriate, for commercial launch and beyond.
Pharmacology
Once we have identified a target with good potency and a reasonable distribution profile, we test them in disease models which reproduce most of the clinical manifestations of the disease. These experiments allow us to evaluate how our compounds perform in disease models and possibly benchmark their activity against that of reference compounds. In the disease models,
we not only seek to improve the efficacy of our compounds, but also investigate
any possible side effects in dedicated safety studies.
Our drug discovery process
more
Under our revenue-sharing agreement, Idorsia is entitled to receive quarterly payments of 8% of the net sales of ponesimod products from Actelion Pharmaceuticals Ltd.
more
Under our revenue-sharing agreement, Idorsia is entitled to receive quarterly payments of 8% of the net sales of ponesimod products from Actelion Pharmaceuticals Ltd.
more
Idorsia and Janssen Biotech, Inc. are jointly developing aprocitentan. Janssen Biotech has sole commercialization rights worldwide. If approved, Idorsia is entitled to tiered royalties on annual net sales.
more
Our rich pipeline means that we will have substantial opportunities to leverage our fit-for-purpose commercial organization. Visit our Development Pipeline page for more about our innovation.
Idorsia entered into a global license agreement with Neurocrine Biosciences for the development and commercialization of ACT-709478, Idorsia’s potent, selective, orally active and brain-penetrating T-type calcium channel blocker.
Our drug discovery process
Contact us online
www.idorsia.de
Targets
Hits
Lead Structure
Improved Leads
Compound Library
Preclinical Development
Drug Development
Clinical Development
Registration
Launch
Molecular Biology
(Target Finding)
Molecular Biology
(Target Finding)
Biochemistry
(High Throughput Screening)
Biochemistry
(High Throughput Screening)
Structural Biology
and Molecular Modeling
Structural Biology
and Molecular Modeling
Research
Information
Management
Research
Information
Management
Medicinal
Chemistry
Medicinal
Chemistry
Pharmacokinetics & Metabolism
Pharmacokinetics & Metabolism
Chemistry
Process R&D
Chemistry
Process R&D
Pharmacology
Pharmacology
Molecular Biology
(Target Finding)
Our work in the lab begins with the target. This may be a particular protein which, when its activity is modulated, can normalize a biological process in the body – with beneficial effects for patients. To see whether we can affect the protein’s activity, we first need to be able to measure it.
We produce, or “express”, the target in large quantities and measure its natural activity in assays. The assay needs to be sensitive, accurate and highly reliable.
Plus, in order to perform hundreds of thousands of measurements, it needs to be automated, using robotic equipment.
Biochemistry
(High Throughput Screening)
But there are two sides to the discovery process – a target and a compound.
Compounds are substances which, we hope, will modify the activity of a target involved in a pathological process and which can be developed into a drug
for patients.
At Idorsia, we maintain a library consisting of hundreds of thousands of different compounds. To begin our hunt for drugs, we test the entire library on the target,
in the hope that one of these compounds will modify the activity of the protein.
This process is called high-throughput screening; if it’s a simple assay, we can test the whole library within a matter of weeks, with the goal of identifying compounds which exhibit activity on the target.
Structural Biology and
Molecular Modeling
Target and compound needs to fit together like a lock and a key. Our experts in structural biology and molecular modeling analyze these compounds – using techniques and tools such as computer-aided drug design – to aid
the optimization process by looking
at 3D shapes, interactions, and properties of the molecules.
Research Information Management
Throughout the drug discovery process, huge amounts of data are generated, and powerful IT tools are required to extract the knowledge we need. To really understand the data, we visualize it and study the relationship between chemical structures and biological properties.
Medicinal chemistry involves the use of chemistry’s tools to design molecules that are potential drugs. Based on the knowledge gained from literature, high-throughput screening results, initial studies, and molecular modeling, we form a hypothesis for analysis. We then enter drug design with the goal of finding the ideal compound – which must not only be potent but have
the right properties such as solubility, stability, bioavailability and selectivity.
The molecules we design are synthesized and then sent back to our biologists or pharmacologists for testing in an iterative process. With each cycle, the compound is further optimized to ultimately deliver a potent, effective and safe drug for development.
Medicinal Chemistry
Pharmacokinetics & Metabolism
At this point, we also study how the drug substance moves through the body. This is vital to understand key factors such as the duration of the treatment effect and intensity, which helps determine the appropriate dose.
Chemistry Process R&D
Small-scale testing for initial assays requires only milligram quantities; for subsequent testing, however, much more material is needed. This is where our process research teams come into the picture. They are responsible for scaling up from milligram to gram quantities, and finally to the kilogram batch which is used for preclinical testing.
It’s no good having a potent compound which is destroyed by the body before it has a chance to do its job. Our chemical and drug product specialists take a compound which has been optimized by the chemists and develop the most robust, safe and cost-efficient processes for the drug substance, the formulation, and packaging materials.
Once reproducible processes have been elaborated to produce large quantities of the active compound and the formulated drug product, our technical project teams manage the production of the drug with partner companies. They secure drug supplies for clinical development and, when appropriate, for commercial launch and beyond.
Pharmacology
Once we have identified a target with good potency and a reasonable distribution profile, we test them in disease models which reproduce most of the clinical manifestations of the disease. These experiments allow us to evaluate how our compounds perform in disease models and possibly benchmark their activity against that of reference compounds. In the disease models,
we not only seek to improve the efficacy of our compounds, but also investigate
any possible side effects in dedicated safety studies.
Targets
Compound Library
Hits
Lead Structure
Improved Leads
Preclinical Development
Drug Development
Clinical Development
Registration
Launch
Molecular Biology
(Target Finding)
Biochemistry (High Throughput Screening)
Structural Biology and Molecular Modeling
Research
Information
Management
Medicinal
Chemistry
Pharmacokinetics & Metabolism
Chemistry
Process R&D
Pharmacology
Our work in the lab begins with the target. This may be a particular protein which, when its activity is modulated, can normalize a biological process in
the body – with beneficial effects for patients. To see whether we can affect the protein’s activity, we first need to be able to measure it.
We produce, or “express”, the target in large quantities and measure its natural activity in assays. The assay needs to be sensitive, accurate and highly reliable. Plus, in order to perform hundreds of thousands of measurements, it needs to be automated, using robotic equipment.
Molecular Biology
(Target Finding)
But there are two sides to the discovery process –
a target and a compound.
Compounds are substances which, we hope,
will modify the activity of a target involved in
a pathological process and which can be developed into a drug for patients.
At Idorsia, we maintain a library consisting of hundreds of thousands of different compounds. To begin our hunt for drugs, we test the entire library on the target, in the hope that one of these compounds will modify the activity of the protein. This process is called high-throughput screening; if it’s a simple assay, we can test the whole library within a matter of weeks, with the goal of identifying compounds which exhibit activity on the target.
Biochemistry (High Throughput Screening)
Structural Biology and
Molecular Modeling
Target and compound needs to fit together like
a lock and a key. Our experts in structural biology and molecular modeling analyze these compounds – using techniques and tools such as computer-aided drug design – to aid the optimization process by looking at 3D shapes, interactions,
and properties of the molecules.
Research Information Management
Throughout the drug discovery process, huge amounts of data are generated, and powerful IT tools are required to extract the knowledge we need. To really understand the data, we visualize it and study the relationship between chemical structures and biological properties.
Medicinal Chemistry
Medicinal chemistry involves the use of chemistry’s tools to design molecules that are potential drugs. Based on the knowledge gained from literature,
high-throughput screening results, initial studies,
and molecular modeling, we form a hypothesis for analysis. We then enter drug design with the goal
of finding the ideal compound – which must not only be potent but have the right properties such as solubility, stability, bioavailability and selectivity.
The molecules we design are synthesized and then sent back to our biologists or pharmacologists for testing in an iterative process. With each cycle,
the compound is further optimized to ultimately deliver a potent, effective and safe drug
for development.
Pharmacokinetics & Metabolism
At this point, we also study how the drug substance moves through the body. This is vital to understand key factors such as the duration of the treatment effect and intensity, which helps determine the appropriate dose.
Chemistry Process R&D
Small-scale testing for initial assays requires only milligram quantities; for subsequent testing, however, much more material is needed. This is where our process research teams come into the picture. They are responsible for scaling up from milligram to gram quantities, and finally to the kilogram batch which is used for preclinical testing.
It’s no good having a potent compound which is destroyed by the body before it has a chance to do its job. Our chemical and drug product specialists take a compound which has been optimized by the chemists and develop the most robust, safe and cost-efficient processes for the drug substance, the formulation,
and packaging materials.
Once reproducible processes have been elaborated to produce large quantities of the active compound and the formulated drug product, our technical project teams manage the production of the drug with partner companies. They secure drug supplies for clinical development and, when appropriate, for commercial launch and beyond.
Pharmacology
Once we have identified a target with good potency and a reasonable distribution profile, we test them in disease models which reproduce most of the clinical manifestations of the disease. These experiments allow us to evaluate how our compounds perform in disease models and possibly benchmark their activity against that of reference compounds. In the disease models, we not only seek to improve the efficacy of our compounds, but also investigate any possible side effects in dedicated safety studies.
More joy –
The spark of passion
“We must integrate computational tools and digital technologies at every stage of the drug discovery, clinical development and commercialization process in order
to maximize our potential to bring breakthrough medicines to patients.”
— Jean-Paul Clozel, CEO
Montreal, Canada
We want our employees to feel proud of their work, and of the company they work for. We provide a supportive and stimulating environment for high-performing teams, recognizing and rewarding their contributions.
Patty Torr
President, Idorsia US
Founded 2022
1155 Rue Metcalfe, Suite 1515
Montréal, QC H2J 2ZS
Canada
Idorsia Pharmaceuticals Canada Ltd
www.idorsia.us
Stockholm, Sweden
Thorsten Löchle
General Manager Germany
Founded 2022
Luise-Ullrich-Strasse 20
DE-80636 München
Germany
Idorsia Pharmaceuticals Nordics AB
www.idorsia.de
Contact us online
Seoul, South Korea
MinBok Lee
General Manager,
Idorsia Korea
Founded 2022
F17, 410 Teheran-Ro
GangNam-Gu, Seoul, 06192
Republic of Korea
Idorsia Pharmaceuticals Korea Co., Ltd
www.idorsia.kr
www.idorsia.it
www.idorsia.es
www.idorsia.uk